Icon
+91 94997 68112
Login Register

Tykerb - (EQ 250MG BASE; Tablet)

Lapatinib Ditosylate Novartis
EQ 250MG BASE; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
Less Than 5
TYKERB is a kinase inhibitor indicated in combination with: • capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. • letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
Yes
***** ** ******** **** ***** ***** * **** ** **** ****** *** *** *** ********* ** ***. ** ****** **** *** ******** ***** **** *** **** ****** ******* ******** ** *** **, **** *** * **** ** **** ******* ******* - *** **, ****; ******* - *** **, ****. **** ******** **** *** ** **** ** ***** **** *** **, ****.
Tykerb Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
***** (*****) **** *** *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** (*****) *** \ ** *** ********* *** ********* ********* ******** ******** ** ** ***, ****
  1. **** **. **** : ***** & ***** ******** ***** ***** ***** **** ** ****** **** ******. ***** *** *** **** * **** ******* ***** & *****.
  2. *** **, **** : **** *** ***** ********. *** ** ** *** *********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.